References
- Manchester KR, Lomas EC, Waters L, et al. The emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug Test Anal. 2018;10(2):392–393.
- Moosmann B, Auwärter V. Designer benzodiazepines: another class of new psychoactive substances. Handb Exp Pharmacol. 2018;252:383–410.
- Bäckberg M, Pettersson Bergstrand M, Beck O, et al. Occurrence and time course of NPS benzodiazepines in Sweden – results from intoxication cases in the STRIDA project. Clin Toxicol (Phila). 2019;57(3):203–212.
- European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances: global markets, global threats and the COVID-19 pandemic; 2021; [cited 2021 Feb 17]. Available from: https://www.emcdda.europa.eu/system/files/publications/13464/20205648_TD0320796ENN_PDF_rev.pdf
- Welsh Emerging Drugs & Identification of Novel Substance Project (WEDINOS). Sample results – keyword search 'flubromazolam'; 2020; [cited 2021 Feb 17]. Available from: https://wedinos.org/db/samples/search
- Andersson M, Kjellgren A. The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. Nordisk Alkohol Nark. 2017;34(3):217–229.
- El Balkhi S, Monchaud C, Herault F, et al. Designer benzodiazepines' pharmacological effects and potencies: how to find the information. J Psychopharmacol. 2020;34(9):1021–1029.
- World Health Organisation. Critical review report: flubromazolam; 2020; [cited 2021 Feb 17]. Available from: https://www.who.int/docs/default-source/controlled-substances/43rd-ecdd/final-flubromazolam-a.pdf?sfvrsn=887bdf43_4
- Noble C, Mardal M, Bjerre Holm N, et al. In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples. Drug Test Anal. 2017;9(8):1182–1191.
- Huppertz LM, Moosmann B, Auwärter V. Flubromazolam – basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal. 2018;10(1):206–211.
- Łukasik-Głębocka M, Sommerfeld K, Teżyk A, et al. Flubromazolam—a new life-threatening designer benzodiazepine. Clin Toxicol (Phila). 2016;54(1):66–68.
- Bohnenberge K, Liu MT. Flubromazolam overdose: a review of a new designer benzodiazepine and the role of flumazenil. Ment Health Clin. 2019;9(3):133–137.
- Hill SL, Najafi J, Dunn M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification of Novel Psychoactive Substances (IONA) study. Clin Toxicol (Phila). 2016;54(8):638–643.
- Høiseth G, Tuv SS, Karinen R. Blood concentrations of new designer benzodiazepines in forensic cases. Forensic Sci Int. 2016;268:35–38.
- Abdul K, Hikin L, Smith P, et al. Flubromazolam: detection in five post-mortem cases. Med Sci Law. 2020;60(4):266–269.